Komori
Treasury Stock4556KAINOS Laboratories,Inc.Pharmaceuticals

Notice Regarding the Cancellation of Treasury Shares

The company has decided to cancel a total of 163,900 shares, including treasury shares held by the company. The cancellation is conditional on the proposal for a share consolidation, with 15 June 2026 as the effective date, being approved at the shareholders’ meeting.

Worth reading
36Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
163900
Shares
Wording
Conditional
How definitive the wording is.

自己株式の消却

Resolved 22 April 2026
CancellationRetired shares are removed from the total number of issued shares and can never return to the market.
3.6%Cancellation of
Number of shares to be retired163,900 shares
Percentage of total issued shares before retirement3.60%
Scheduled retirement date12 June 2026
Total number of issued shares after retirement4,394,960 shares
Reference (number of shares stated in the document)
Current number of treasury shares109,700 shares as of 10 April 2026. All of these shares, together with the 54,200 shares held by Trust Account E as trust assets under the Stock Benefit Trust (BBT), will be cancelled. The total number of shares subject to cancellation, including the shares held in trust, is 163,900.
自己株式の消却
ItemDetails
Resolution date22 April 2026
Number of shares to be retired163,900 shares
Percentage of total issued shares before retirement3.60%
Scheduled retirement date12 June 2026
Total number of issued shares after retirement4,394,960 shares
Current number of treasury shares109,700 shares as of 10 April 2026. All of these shares, together with the 54,200 shares held by Trust Account E as trust assets under the Stock Benefit Trust (BBT), will be cancelled. The total number of shares subject to cancellation, including the shares held in trust, is 163,900.
Items this document does not state (10)
Class of shares to be acquiredMaximum number of shares to be acquiredPercentage of total issued sharesTotal acquisition priceAcquisition periodMethod of acquisitionReason for acquisitionTotal number of issued sharesChange in acquisition periodChange in acquisition limit

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The treasury shares will be cancelled conditional on approval of the proposals concerning the share consolidation, the abolition of the provisions regarding the number of shares per trading unit, and partial amendments to the Articles of Incorporation. No specific reason for the cancellation of the treasury shares is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Cancellation of Treasury Shares | KAINOS Laboratories,Inc. (4556) timely disclosure | Komori